Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors

Core Insights - Lifordi Immunotherapeutics has secured a strategic investment from Sanofi Ventures, along with additional funding from existing investors, totaling $112 million to support its clinical development efforts [1][6][7] Group 1: Investment Details - The investment from Sanofi Ventures and existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture will support an ongoing Phase 1 study of LFD-200, an antibody-drug conjugate (ADC) targeting rheumatoid arthritis [1][6] - The funding will also facilitate Chemistry Manufacturing and Controls (CMC) preparations to ensure timely availability of Phase 2 clinical supplies [1][6] Group 2: Clinical Development - The Phase 1 study of LFD-200 is progressing as planned, with initial data from healthy participants expected in the coming months [6][7] - Preclinical studies have shown efficacy in multiple disease models by targeting myeloid and lymphoid cells using a specific cell surface membrane protein [7] Group 3: Company Overview - Lifordi Immunotherapeutics is focused on developing ADCs for autoimmune and inflammatory disorders, leveraging a novel drug delivery platform applicable to various payloads [7] - The company is backed by experienced drug developers in immunology and inflammatory diseases, along with a strong track record in partnerships and funding [7]